XBP1 and metabolic dysfunction-associated steatotic liver disease: As shown in Table 1, the FFC diet significantly increased NAFLD scores (NAS > 5) compared with CD, whereas FT@XBP1 treatment remarkably reduced NAS compared with mice fed with an FFC diet or treated with FT@NC (P = 0.003), as demonstrated by evident reduced lobular inflammation and steatosis.